Posted by Michael Wonder on 24 Apr 2016
Outcomes from the PTAC February 2016 meeting
22 April 2016 - The outcomes from the February 2016 PTAC meeting are now available.
The PTAC has recommended that ipilimumab (Yervoy) be funded with a low priority for the treatment of patients with previously treated unresectable stage IIIc or IV melanoma.
For more details, go to: http://www.pharmac.govt.nz/assets/ptac-minutes-2016-02.pdf
